Price T Rowe Associates Inc Sellas Life Sciences Group, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
37Shares Held
4.37MCall Options Held
3.28MPut Options Held
56.3K-
Vanguard Group Inc Valley Forge, PA1.79MShares$2.14 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA517KShares$620,4090.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$516,4410.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$370,1593.71% of portfolio
-
Opus Capital Group, LLC221KShares$265,2000.04% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.7M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...